Dr. Marc  Poirot

Dr. Marc Poirot

Research Director/VP of Research
Institut National de la Sante et de la Recherche Medicale, France


Highest Degree
Ph.D. in Chemistry from Universite Paul Sabatier, Toulouse, France

Share this Profile

Biography

Dr. Marc Poirot is Research Director at the Institute National de la Santé et de la Recherche Medicale (INSERM). He Heads the team Sterol Metabolism and Therapeutic Innovations in Oncology (Toulouse, France) with Dr. Sandrine Silvente-Poirot at the Cancer Research Center of Toulouse. He received a PhD in Chemical Biology (1991) from the University of Toulouse (France). He did a Post-doctorate at Sanofi in 1991 before becoming tenured at INSERM. He was Visiting Scientist in the laboratory of Dr Stoney S. Simons Jr (NIDDK/NIH, Bethesda, USA) to study Steroid Hormone Receptors. Since then, his research has focused on the identification of off-targets of the anti-tumor drug tamoxifen, which led to the definition of the importance of Cholesterol Metabolism in the Pharmacology of Antiestrogens. He trained 10 of postgraduate students. He has published 68 SCI journal paper. He also served as an evaluation expert for organizations. He is co-founder of the Biotech Company Affichem, which develops small natural molecules for therapeutic applications. He is member of the executive board and chairman of the scientific board of Affichem, Innovative, translational and longstanding research has ever been a pursuit in his academic career. He is associate editor for Frontiers in Nutrition, Frontiers in Pharmacology, Frontiers in Chemistry, Frontiers in Oncology, Nature publishing group. He is also serving as reviewer and editor of number of journals. He is member of Groupe de recherche sur les lipides, Société Française de Chimie Therapeutique, American Association for Cancer Research, American Society of Pharmacology and Experimental Therapeutics, European Network on Oxysterol Research, and Asian Council of Science Editors.

Area of Interest:

Chemistry
100%
Drug Design Discovery
62%
Pharmacology
90%
Medicinal Chemistry
75%
Cholesterol Metabolism
55%

Education

1991

Ph.D.

Universite Paul Sabatier, Toulouse, France

Chemistry

Selected Publications

  1. Taddeo, V.A., F. Epifano, F. Preziuso, S. Fiorito and N. Caron et al., 2019. HPLC analysis and skin whitening effects of umbelliprenin-containing extracts of Anethum graveolens, Pimpinella anisum and Ferulago campestris. Molecules, Vol. 24. 10.3390/molecules24030501.
    CrossRef  |  Direct Link  |  

  2. Khallouki, F., R.W. Owen, M. Akdad, H. Hajji, S. Silvente-Poirot and M. Poirot, 2019. Vitamin E: An Overview. In: Molecular Nutrition: Vitamins, Patel, V., (Ed.). Elsevier Publisher, UK, ISBN- 9780128119075,.

  3. Genovese, S., F. Epifano, P. de Medina, N. Caron and A. Rives et al., 2019. Natural and semisynthetic oxyprenylated aromatic compounds as stimulators or inhibitors of melanogenesis. Bioorg. Chem., 87: 181-190.
    CrossRef  |  Direct Link  |  

  4. Silvente-Poirot, S., G. Segala, M.C. Poirot and M. Poirot, 2018. Ligand-dependent transcriptional induction of lethal autophagy: A new perspective for cancer treatment. Autophagy, 14: 555-557.
    CrossRef  |  Direct Link  |  

  5. Silvente-Poirot, S., F. Dalenc and M. Poirot, 2018. The effects of cholesterol-derived oncometabolites on nuclear receptor function in cancer. Cancer Res., 78: 4803-4808.
    CrossRef  |  Direct Link  |  

  6. Record, M., S. Silvente-Poirot, M. Poirot and M.J. Wakelam, 2018. Extracellular vesicles: Lipids as key components of their biogenesis and functions. J. Lipid Res., 59: 1316-1324.
    CrossRef  |  Direct Link  |  

  7. Poirot, M., R. Soules, A. Mallinger, F. Dalenc and S. Silvente-Poirot, 2018. Chemistry, biochemistry, metabolic fate and mechanism of action of 6-oxo-cholestan-3β, 5α-diol (OCDO), a tumor promoter and cholesterol metabolite. Biochimie, 153: 139-149.
    CrossRef  |  Direct Link  |  

  8. Poirot, M., 2018. Meet our editorial board member. Nat. Prod. J., 8: 1-1.
    CrossRef  |  Direct Link  |  

  9. Poirot, M. and S. Silvente-Poirot, 2018. The tumor-suppressor cholesterol metabolite, dendrogenin A, is a new class of LXR modulator activating lethal autophagy in cancers. Biochem. Pharmacol., 153: 75-81.
    CrossRef  |  Direct Link  |  

  10. Khallouki, F., R. Owen, S. Silvente-Poirot and M. Poirot, 2018. Bryonolic acid blocks cancer cell clonogenicity and invasiveness through the inhibition of fatty acid: Cholesteryl ester formation. Biomedicines, Vol. 6. 10.3390/biomedicines6010021.
    CrossRef  |  Direct Link  |  

  11. Voisin, M., P. de Medina, A. Mallinger, F. Dalenc and E. Huc-Claustre et al., 2017. Identification of a tumor-promoter cholesterol metabolite in human breast cancers acting through the glucocorticoid receptor. Proc. Natl. Acad. Sci., 114: E9346-E9355.
    CrossRef  |  Direct Link  |  

  12. Soules, R., E. Noguer, L. Iuliano, C. Zerbinati and J. Leignadier et al., 2017. Improvement of 5, 6α-epoxycholesterol, 5, 6β-epoxycholesterol, cholestane-3β, 5α, 6β-triol and 6-oxo-cholestan-3β, 5α-diol recovery for quantification by GC/MS. Chem. Phys. Lipids, 207: 92-98.
    CrossRef  |  Direct Link  |  

  13. Segala, G., M. David, P. de Medina, M.C. Poirot and N. Serhan et al., 2017. Dendrogenin A drives LXR to trigger lethal autophagy in cancers. Nat. Commun., Vol. 8. 10.1038/s41467-017-01948-9.
    CrossRef  |  Direct Link  |  

  14. Noguer, E., R. Soules, C. Netter, C. Nagarathinam and J. Leignadier et al., 2017. Quantitative analysis of the tumor suppressor dendrogenin A using liquid chromatography tandem mass spectrometry. Chem. Phys. Lipids, 207: 81-86.
    CrossRef  |  Direct Link  |  

  15. Leignadier, J., F. Dalenc, M. Poirot and S. Silvente-Poirot, 2017. Improving the efficacy of hormone therapy in breast cancer: The role of cholesterol metabolism in SERM-mediated autophagy, cell differentiation and death. Biochem. Pharmacol., 144: 18-28.
    CrossRef  |  Direct Link  |  

  16. Khallouki, F., R.W. Owen, S. Silvente-Poirot, H. Hajji and M. Poirot, 2017. Functional Food for the Prevention and Management of Cancer. In: Functional Foods and Cancer: Bioactive Compounds and Cancer, Martirosyan, D.M. and Z. Jin-Rong, (Eds.). Food Science Publisher, USA, ISBN-13: 978-1975953171, pp: 278-319.

  17. Dalenc, F., L. Iuliano, T. Filleron, C. Zerbinati and M. Voisin et al., 2017. Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study. J. Steroid Biochem. Mol. Biol., 169: 210-218.
    CrossRef  |  Direct Link  |  

  18. Poirot, M. and S. Silvente-Poirot, 2016. When cholesterol meets histamine, it gives rise to dendrogenin A: A tumour suppressor metabolite1. Biochem. Soc. Trans., 44: 631-637.
    CrossRef  |  Direct Link  |  

  19. Klionsky, D.J., K. Abdelmohsen, A. Abe, M.J. Abedin and H. Abeliovich et al., 2016. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 12: 1-222.
    CrossRef  |  

  20. Khallouki, F., P. de Medina, S. Caze-Subra, K. Bystricky, P. Balaguer, M. Poirot and S. Silvente-Poirot, 2016. Molecular and biochemical analysis of the estrogenic and proliferative properties of vitamin e compounds. Frontiers Oncol., Vol. 5. .
    Direct Link  |  

  21. Tosolini, M., F. Pont, D. Betous, E. Ravet and L. Ligat et al., 2015. Human monocyte recognition of adenosine-based cyclic di-nucleotides unveils the A2a GPCR tonic inhibition of mitochondrial-induced cell death. Mol. Cell Biol., 35: 479-495.
    Direct Link  |  

  22. Iuliano, L., P.J. Crick, C. Zerbinati, L. Tritapepe and J. Abdel-Khalik et al., 2015. Cholesterol metabolites exported from human brain. Steroids, 99: 189-193.
    CrossRef  |  Direct Link  |  

  23. Fransson, A., P. de Medina, M.R. Paillasse, S. Silvente-Poirot, M. Poirot and M. Ulfendahl, 2015. Dendrogenin A and B two new steroidal alkaloids increasing neural responsiveness in the deafened guinea pig. Front. Aging Neurosci., Vol. 7. .
    Direct Link  |  

  24. Dalenc, F., M. Poirot and S. Silvente-Poirot, 2015. Dendrogenin A: A mammalian metabolite of cholesterol with tumor suppressor and neurostimulating properties. Curr. Med. Chem., 22: 3533-3549.
    Direct Link  |  

  25. Voisin, M., S. Silvente-Poirot and M. Poirot, 2014. One step synthesis of 6-oxo-cholestan-3β, 5α-diol. Biochem. Biophys. Res. Commun., 446: 782-785.
    CrossRef  |  Direct Link  |  

  26. Silvente-Poirot, S. and M. Poirot, 2014. Cholesterol and cancer in the balance. Science, 343: 1445-1446.
    Direct Link  |  

  27. Record, M., M. Poirot and S. Silvente-Poirot, 2014. Emerging concepts on the role of exosomes in lipid metabolic diseases. Biochimie, 96: 67-74.
    CrossRef  |  Direct Link  |  

  28. Record, M., K. Carayon, M. Poirot and S. Silvente-Poirot, 2014. Exosomes as new vesicular lipid transporters involved in cell-cell communication and various pathophysiologies. Biochimica Biophysica Acta (BBA)-Mol. Cell Biol. Lipids, 1841: 108-120.
    CrossRef  |  PubMed  |  Direct Link  |  

  29. Khalifa, S.A.M., P. de Medina, A. Erlandsson, H.R. El Seedi, S. Silvente-Poirot and M. Poirot, 2014. The novel steroidal alkaloids dendrogenin A and B promote proliferation of adult neural stem cells. Biochem. Biophys. Res. Commun., 446: 681-686.
    CrossRef  |  

  30. Sola, B., M. Poirot, P. de Medina, S. Bustany, V. Marsaud, S. Silvente-Poirot and J.M. Renoir, 2013. Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolism. Oncotarget, 4: 911-922.
    PubMed  |  Direct Link  |  

  31. Segala, G., P. de Medina, L. Iuliano, C. Zerbinati and M.R. Paillasse et al., 2013. 5,6-Epoxy-cholesterols contribute to the anticancer pharmacology of Tamoxifen in breast cancer cells. Biochem. Pharmacol., 86: 175-189.
    CrossRef  |  PubMed  |  Direct Link  |  

  32. Poirot, M. and S. Silvente-Poirot, 2013. Oxysterols and related sterols: Implication in physiopathology and pharmacology. Biochem. Pharmacol., 86: 1-2.

  33. Mauxion, T., J. Barbet, J. Suhard , J.P. Pouget, M. Poirot and M. Bardies, 2013. Improved realism of hybrid mouse models may not be sufficient to generate reference dosimetric data. Med. Phys., Vol., 40. 10.1118/1.4800801.
    CrossRef  |  PubMed  |  Direct Link  |  

  34. De Medina, P., M. Paillasse, G. Segala, M. Voisin and L. Mhamdi et al., 2013. Discovery of Dendrogenin A: A new cholesterol metabolite that triggers antitumor activities. Nat. Commun., Vol., 4 .

  35. Chapuy-Regaud, S., C. Subra, M. Requena, P. de Medina and S. Amara et al., 2013. Progesterone and a phospholipase inhibitor increase the endosomal bis(monoacylglycero)phosphate content and block HIV viral particle intercellular transmission. Biochimie, 95: 1677-1688.
    CrossRef  |  PubMed  |  Direct Link  |  

  36. Silvente-Poirot, S. and M. Poirot, 2012. Cholesterol metabolism and cancer: The good, the bad and the ugly. Curr. Opin. Pharmacol., 12: 673-676.
    CrossRef  |  PubMed  |  Direct Link  |  

  37. Silvente-Poirot, S. and M. Poirot, 2012. Cholesterol epoxide hydrolase and cancer. Curr. Opin. Pharmacol., 12: 696-703.
    CrossRef  |  PubMed  |  Direct Link  |  

  38. Poirot, M., S. Silvente-Poirot and R.R. Weichselbaum, 2012. Cholesterol metabolism and resistance to tamoxifen in breast cancers. Curr. Opin. Pharmacol., 12: 683-689.
    CrossRef  |  PubMed  |  Direct Link  |  

  39. Poirot, M. and S. Silvente-Poirot, 2012. Cholesterol-5,6-epoxides: Chemistry, biochemistry, metabolic fate and cancer. Biochimie, 95: 622-631.
    CrossRef  |  PubMed  |  Direct Link  |  

  40. Paillasse, M.R., N. Saffon, H. Gornitzka, S. Silvente-Poirot, M. Poirot and P. de Medina, 2012. Surprising unreactivity of cholesterol-5,6-epoxides towards nucleophiles. J. Lipid Res., 53: 718-725.
    CrossRef  |  PubMed  |  Direct Link  |  

  41. Paillas, S., A. Causse, P. de Medina, M. Poirot and V. Denis et al., 2012. MAPK14 p38alpha confers Irinotecan resistance to tp53-defective cells by inducing survival autophagy. Autophagy, 8: 1098-1112.

  42. Klionsky, D.J., F.C. Abdalla, H. Abeliovich, R.T. Abraham and A. Acevedo-Arozena et al., 2012. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 8: 445-544.
    PubMed  |  Direct Link  |  

  43. Guyot, E., X. Coumoul, J.F. Chasse, F. Khallouki, J.F. Savouret, M. Poirot, R. Barouki, 2012. Identification of a new stilbene-derived inducer of paraoxonase 1 and ligand of the Aryl hydrocarbon Receptor. Biochem. Pharmacol., 83: 627-632.
    CrossRef  |  PubMed  |  Direct Link  |  

  44. De Medina, P., M.R. Paillasse, G. Segala, T. al Saati and J. Boyes et al., 2012. Technical note: Hapten synthesis, antibody production and development of an enzyme-linked immunosorbent assay for detection of the natural steroidal alkaloid Dendrogenin A. Biochimie, 95: 482-488.
    CrossRef  |  PubMed  |  Direct Link  |  

  45. Record, M., C. Subra, S. Silvente-Poirot and M. Poirot, 2011. Exosomes as intercellular signalosomes and pharmacological effectors. Biochem. Pharmacol., 81: 1171-1182.
    Direct Link  |  

  46. Jordan, V.C., 2011. Four decades of discovery in breast cancer research and treatment--an interview with V. Craig Jordan. Interview by Marc Poirot. Int. J. Dev. Biol., 55: 703-712.
    CrossRef  |  PubMed  |  Direct Link  |  

  47. De Medina, P., M.R. Paillasse, G. Segala, F. Khallouki and S. Brillouet et al., 2011. Importance of cholesterol and oxysterols metabolism in the pharmacology of tamoxifen and other AEBS ligands. Chem. Phys. Lipids, 164: 432-437.
    CrossRef  |  PubMed  |  Direct Link  |  

  48. Subra, C., D. Grand, K. Laulagnier, A. Stella and G. Lambeau et al., 2010. Exosomes account for vesicle-mediated transcellular transport of activatable phospholipases and prostaglandins. J. Lipid Res., 51: 2105-2120.
    CrossRef  |  PubMed  |  Direct Link  |  

  49. Dorbes, S., B. Mestre-Voegtle, Y. Coulais, C. Picard, S. Silvente-Poirot, M. Poirot and E. Benoist, 2010. Synthesis, characterization and In vitro evaluation of new oxorhenium- and oxotechnetium-CCK4 derivatives as molecular imaging agents for CCK2-receptor targeting. Eur. J. Med. Chem., 45: 423-429.
    CrossRef  |  PubMed  |  Direct Link  |  

  50. De Medina, P., S. Genovese, M.R. Paillasse, M. Mazaheri and S. Caze-Subra et al., 2010. Auraptene is an inhibitor of cholesterol esterification and a modulator of estrogen receptors. Mol. Pharmacol., 78: 827-836.
    CrossRef  |  PubMed  |  Direct Link  |  

  51. De Medina, P., M.R. Paillasse, S. Segala, M. Poirot and S. Silvente-Poirot, 2010. Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands. Proc. Natl. Acad. Sci. USA., 107: 13520-13525.
    CrossRef  |  PubMed  |  Direct Link  |  

  52. Brillouet, S., S. Dorbes, S. Silvente-Poirot, B. Mestre-Voegtle, C. Picard, M. Poirot and F. Courbon, 2010. Peptidic targeting in nuclear oncology: Interest of molecular modelling. Med. Nul. Imagerie Function.Metabol., 34: 289-294.

  53. Brillouet, S., S. Dorbes, F. Courbon, C. Picard and J.P. Delord et al., 2010. Development of a new radioligand for cholecystokinin receptor subtype 2 scintigraphy: From molecular modeling to In vivo evaluation. Bioorg. Med. Chem., 18: 5400-5412.
    CrossRef  |  

  54. Paillasse, M.R., P. de Medina, G. Amouroux, L. Mhamdi, M. Poirot and S. Silvente-Poirot, 2009. Signaling through cholesterol esterification: A new pathway for the cholecystokinin 2 receptor involved in cell growth and invasion. J. Lipid Res., 50: 2203-2211.
    CrossRef  |  PubMed  |  Direct Link  |  

  55. De Medina, P., S. Silvente-Poirot and M. Poirot, 2009. Tamoxifen and AEBS ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation. Autophagy, 5: 1066-1067.
    CrossRef  |  PubMed  |  Direct Link  |  

  56. De Medina, P., M. Paillasse, B. Payre, S. Silvente-Poirot and M. Poirot, 2009. Synthesis of new alkylaminooxysterols with potent cell differentiating activities: Identification of leads for the treatment of cancer and neurodegenerative diseases. J. Med. Chem., 52: 7765-7777.
    CrossRef  |  PubMed  |  Direct Link  |  

  57. De Medina, P., B. Payre, N. Boubekeur, J. Bertrand-Michel and F. Terce, S. Silvente-Poirot and M. Poirot, 2009. Ligands of the antiestrogen-binding site induce active cell death and autophagy in human breast cancer cells through the modulation of cholesterol metabolism. Cell Death Differ., 16: 1372-1384.
    CrossRef  |  PubMed  |  Direct Link  |  

  58. Payre, B., P. de Medina, N. Boubekeur, L. Mhamdi and J. Bertrand-Michel et al., 2008. Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism. Mol. Cancer Ther., 7: 3707-3717.
    PubMed  |  Direct Link  |  

  59. Brillouet, S., O. Caselles, L.O. Dierickx, B. Mestre and J. Nalis et al., 2007. Preclinical evaluation of new radioligand of cholecystokinin/gastrin receptors in endocrine tumors xenograft nude mice. Nucl. Inst. Meth. Phys. Res. Sect. A: Accelerat. Spectromet. Detect. Assoc. Equip., 571: 160-164.
    CrossRef  |  Direct Link  |  

  60. Savouret, J.F., R. Casper and M. Poirot, 2006. Resveratrol and its derivatives: A new family of antagonists of the aryl hydrocarbon receptor. Actualitu. Chimiqu., 303: 34-36.

  61. Paillasse, M.R., C. Deraeve, P. de Medina, L. Mhamdi, G. Favre, M. Poirot and S. Silvente-Poirot, 2006. Insights into the cholecystokinin 2 receptor binding site and processes of activation. Mol. Pharmacol., 70: 1935-1945.
    CrossRef  |  PubMed  |  Direct Link  |  

  62. De Medina, P., N. Boubekeur, P. Balaguer, G. Favre, S. Silvente-Poirot and M. Poirot, 2006. The prototypical inhibitor of cholesterol esterification, Sah 58-035 [3-[decyldimethylsilyl]-N-[2-(4-methylphenyl)-1-phenylethyl]propanamide], is an agonist of estrogen receptors. J. Pharmacol. Exp. Ther., 319: 139-149.
    CrossRef  |  PubMed  |  Direct Link  |  

  63. De Medina, P., R. Casper, J.F. Savouret and M. Poirot, 2005. Synthesis and biological properties of new stilbene derivatives of resveratrol as new selective aryl hydrocarbon modulators. J. Med. Chem., 48: 287-291.
    CrossRef  |  PubMed  |  Direct Link  |  

  64. Dalenc, F., C. Giamarchi, M. Petit, M. Poirot, G. Favre and J.C. Faye, 2005. Farnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways. Breast Cancer Res., 7: R1159-R1167.
    CrossRef  |  PubMed  |  Direct Link  |  

  65. Kedjouar, B., P. De Medina, M. Oulad-Abdelghani, B. Payre and S. Silvente-Poirot et al., 2004. Molecular characterization of the microsomal tamoxifen binding site. J. Biol. Chem., 279: 34048-34061.
    CrossRef  |  PubMed  |  Direct Link  |  

  66. De Medina, P., G. Favre and M. Poirot, 2004. Multiple targeting by the antitumor drug tamoxifen: a structure-activity study. Curr. Med. Chem. Anticancer Agents, 4: 491-508.
    CrossRef  |  PubMed  |  Direct Link  |  

  67. De Medina, P., B.L. Payre, J. Bernad, I. Bosser and B. Pipy et al., 2004. Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells. J. Pharmacol. Exp. Ther., 308: 1165-1173.
    CrossRef  |  PubMed  |  Direct Link  |  

  68. Garnier, M., C. Giamarchi, I. Delrieu, M.C. Rio and P. Chinestra et al., 2003. Insulin and estrogen receptor ligand influence the FGF-2 activities in MCF-7 breast cancer cells. Biochem. Pharmacol., 65: 629-636.
    CrossRef  |  PubMed  |  Direct Link  |  

  69. Gales, C., M. Poirot, J. Taillefer, B. Maigret and J. Martinez et al., 2003. Identification of tyrosine 189 and asparagine 358 of the cholecystokinin 2 receptor in direct interaction with the crucial C-terminal amide of cholecystokinin by molecular modeling, site-directed mutagenesis and structure/affinity studies. Mol. Pharmacol., 63: 973-982.
    CrossRef  |  PubMed  |  Direct Link  |  

  70. Gales, C., D. Sanchez, M. Poirot, S. Pyronnet and L. Buscail et al., 2003. High tumorigenic potential of a constitutively active mutant of the cholecystokinin 2 receptor. Oncogene, 22: 6081-6089.
    CrossRef  |  PubMed  |  Direct Link  |  

  71. Doisneau-Sixou, S.F., P. Cestac, S. Chouini, J.S. Carroll and A.D. Hamilton et al., 2003. Contrasting effects of prenyltransferase inhibitors on estrogen-dependent cell cycle progression and estrogen receptor-mediated transcriptional activity in MCF-7 cells. Endocrinology, 144: 989-998.
    PubMed  |  Direct Link  |  

  72. Mesange, F., M. Sebbar, J. Capdevielle, J.C. Guillemot, P. Ferrara, F. Bayard, M. Poirot and J.C. Faye, 2002. Identification of two tamoxifen target proteins by photolabeling with 4-(2-morpholinoethoxy)benzophenone. Bioconjug. Chem., 13: 766-772.
    CrossRef  |  PubMed  |  Direct Link  |  

  73. Darblade, B., D. Caillaud, M. Poirot, M. Fouque and J.C. Thiers et al., 2001. Alteration of plasmalemmal caveolae mimics endothelial dysfunction observed in atheromatous rabbit aorta. Cardiovasc. Res., 50: 566-576.
    PubMed  |  Direct Link  |  

  74. Poirot, M., P. De Medina, F. Delarue, J.J. Perie, A. Klaebe and J.C. Faye, 2000. Synthesis, binding and structure-affinity studies of new ligands for the microsomal anti-estrogen binding site (AEBS). Bioorg. Med. Chem., 8: 2007-2016.
    CrossRef  |  PubMed  |  Direct Link  |  

  75. Kedjouar, B., S. Daunes, B.J. Vilner, W.D. Bowen, A. Klaebe, J.C. Faye and M. Poirot, 1999. Structural similitudes between cytotoxic antiestrogen-binding site (AEBS) ligands and cytotoxic sigma receptor ligands. Evidence for a relationship between cytotoxicity and affinity for AEBS or sigma-2 receptor but not for sigma-1 receptor. Biochem. Pharmacol., 58: 1927-1939.
    CrossRef  |  PubMed  |  Direct Link  |  

  76. Delarue, F., B. Kedjouar, F. Mesange, F. Bayard, J.C. Faye and M. Poirot, 1999. Modifications of benzylphenoxy ethanamine antiestrogen molecules: Influence affinity for antiestrogen binding site (AEBS) and cell cytotoxicity. Biochem. Pharmacol., 57: 657-661.
    CrossRef  |  PubMed  |  Direct Link  |  

  77. Plisov, S.Y., M.E. Poirot, K.J. Modarress, A.H. Cavanaugh, D.P. Edwards and S.S. Simons Jr., 1998. Different populations of progesterone receptor-steroid complexes in binding to specific DNA sequences: Effects of salts on kinetics and specificity. J. Steroid Biochem. Mol. Biol., 67: 251-266.
    CrossRef  |  PubMed  |  Direct Link  |  

  78. Mesange, F., M. Sebbar, B. Kedjouar, J. Capdevielle and J.C. Guillemot et al., 1998. Microsomal epoxide hydrolase of rat liver is a subunit of theanti-oestrogen-binding site. Biochem. J., 334: 107-112.
    PubMed  |  Direct Link  |  

  79. Poirot, M., C. Chailleux, F. Mesange, F. Bayard and J.C. Faye, 1994. Characterization of the membranous antiestrogen binding protein: II Purification to homogeneity. J. Recept. Res., 14: 37-46.
    CrossRef  |  PubMed  |  Direct Link  |  

  80. Chailleux, C., M. Poirot, F. Mesange, F. Bayard and J.C. Faye, 1994. Characterization of the membranous antiestrogen binding protein: I. Partial purification of the protein in its active state. J. Recept. Res., 14: 23-35.
    PubMed  |  Direct Link  |  

  81. Betbeder, D., J.J. Perie, T. Baltz, M. Poirot and J.C. Faye, 1993. Characterization of a benzyl-phenoxy-ethanamine binding protein in Trypanosoma equiperdum and the possible relation between binding affinity and trypanocidal activity. Mol. Biochem. Parasitol., 58: 311-316.
    CrossRef  |  PubMed  |  Direct Link  |  

  82. Poirot, M., C. Chailleux, F. Bayard and J.C. Faye, 1992. Cytosolic type II estrogen binding site in rat uterus: Specific photolabeling with estrone. J. Recept. Res., 12: 217-231.
    CrossRef  |  PubMed  |  Direct Link  |  

  83. Garnier, M., M. Poirot, F. Bayard and J.C. Faye, 1991. A Mr 45,000 secreted protein is specifically induced by tamoxifen: Identification in the human breast cancer cell line, MCF-7, adapted to grow in chemically defined medium. J. Cell. Pharmacol., 2: 83-91.

  84. Poirot, M., M. Garnier, F. Bayard, I. Riviere and M. Traore et al., 1990. The anti-proliferative properties of 4-benzylphenoxy ethanamine derivatives are mediated by the anti-estrogen binding site (ABS), whereas the anti-estrogenic effects of trifluopromazine are not. Biochem. Pharmacol., 40: 425-429.
    CrossRef  |  PubMed  |  Direct Link  |  

  85. Poirot, M., C. Chailleux, A. Fargin, F. Bayard and J.C. Faye, 1990. A potent and selective photoaffinity probe for the anti-estrogen binding site of rat liver. J. Biol. Chem., 265: 17039-17043.
    PubMed  |  Direct Link  |  

  86. Fargin, A., F. Bayard, J.C. Faye, M. Traore, M. Poirot, A. Klaebe and J.J. Perie, 1988. Further evidence for a biological role of anti-estrogen-binding sites in mediating the growth inhibitory action of diphenylmethane derivatives. Chem. Biol. Interact, 66: 101-109.
    CrossRef  |  PubMed  |  Direct Link  |